- SynSmart Rasayan Research and Amporin Pharmaceuticals have entered a collaboration to develop small molecule therapeutics for degenerative diseases.
- SynSmart will synthesize a library of novel membrane-protecting molecules, with potential expansion into ADME-PK and candidate selection activities.
SynSmart Rasayan Research Private Limited has entered into a collaboration with Amporin Pharmaceuticals AG to develop small-molecule therapeutics targeting degenerative diseases. The agreement focuses on synthesizing novel membrane-protecting molecules and advancing them through early-stage drug discovery workflows.
Under the collaboration, SynSmart will generate a library of compounds at its research facility in Mumbai, India. These molecules will be screened to identify potential candidates, with the possibility of extending the work into follow-on chemistry and ADME-PK studies to support progression toward candidate selection.
The collaboration aims to accelerate the development of disease-modifying treatments across multiple degenerative conditions. By combining SynSmart’s synthesis capabilities with Amporin’s platform, the partners intend to advance screening, optimization, and selection processes in parallel.
“This collaboration is a testimony of value that SynSmart can bring to the table for its partners. With lab operations running in multi-shift mode and lean team hierarchy, the speed and cost-savings help partners get more done for less.”
Saurabh Kapure, CEO at SynSmart
